Skip to content
Inspirna Inspirna
  • Our Company
    • Our Management Team
    • Clinical Advisory Board
    • Board of Directors
    • Investors
  • Our Science
    • Discovery Platform
    • Presentations & Publications
  • Pipeline
    • Ompenaclid (RGX-202)
    • Abequolixron (RGX-104)
    • RGX-019 ADC
  • Patients
  • Careers
  • News & Events
    • News
    • Events
Menu

Month: November 2017

Rgenix Reports Phase I Data for Cancer Compound RGX-104

Rgenix Inc. (New York, N.Y.) reported preliminary data from a Phase Ia/Ib trial showing that oral RGX-104 led to 4 cases of stable disease among 12 evaluable patients with advanced solid malignancies and lymphoma. To read the full article, please click here.

Liver X Factor

How Rgenix’s Liver X Agonist Could Help Overcome Checkpoint Resistance in Cancer. To read the full article, please click here.

  • 310 E 67th St, Suite 1-12
    New York, NY 10065
  • (646) 856-9261
  • info@inspirna.com
  • Linked In
  • Twitter

Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need.

  • Privacy Policy
  • Terms of Use